1E Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- 1E Therapeutics's estimated annual revenue is currently $10.3M per year.
- 1E Therapeutics's estimated revenue per employee is $201,000
Employee Data
- 1E Therapeutics has 51 Employees.
- 1E Therapeutics grew their employee count by -12% last year.
1E Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Researcher | Reveal Email/Phone |
1E Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $16.7M | 83 | -34% | $237M | N/A |
#2 | $7.8M | 39 | -2% | N/A | N/A |
#3 | $33.8M | 168 | 24% | N/A | N/A |
#4 | $11.3M | 56 | 19% | N/A | N/A |
#5 | $10.3M | 51 | -12% | N/A | N/A |
#6 | $11.7M | 58 | 1060% | N/A | N/A |
#7 | $9.6M | 48 | 41% | N/A | N/A |
What Is 1E Therapeutics?
1E Therapeutics (1Etx) is a breakthrough, clinical stage drug development company creating first-in-class RNA-targeting therapeutics based on our proprietary drug design platform. 1E is the culmination of years of innovation, effort, and tens of millions of $US investment in research and development. 1E's proprietary and groundbreaking rapid drug design process has proven uniquely able to develop innovative drugs that address chronic life threatening indications as well as emerging and evolving pathogens. 1E already has lead compounds that address a wide array of indications in oncology and age-related diseases, immunology, anti-microbial resistance, viral infections, and orphan neurological disorders. 1E’s most advanced lead is already in a Phase 1/2 clinical trial, and the company is positioned to have multiple programs in the clinic within the next 2 years.
keywords:N/A
N/A
Total Funding
51
Number of Employees
$10.3M
Revenue (est)
-12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
1E Therapeutics News
Proteins have shown promise as therapeutics and diagnostics, but their effectiveness is limited by our inability to spatially ... 1E, SI Appendix, Fig.
We also evaluated eighteen clinical-stage therapeutic antibody products and an antibody ... 1E (2.0- and 3.6-fold difference, respectively).
Other Companies in Rehovot
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 56 | -8% | N/A |
#2 | $8.7M | 56 | 8% | N/A |
#3 | $9.1M | 59 | -23% | N/A |
#4 | $9.1M | 59 | -23% | N/A |
#5 | $9.2M | 60 | -9% | N/A |